OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Oncolytic viruses: challenges and considerations in an evolving clinical landscape
Ulrich M. Lauer, Julia Beil
Future Oncology (2022) Vol. 18, Iss. 24, pp. 2713-2732
Open Access | Times Cited: 45
Ulrich M. Lauer, Julia Beil
Future Oncology (2022) Vol. 18, Iss. 24, pp. 2713-2732
Open Access | Times Cited: 45
Showing 1-25 of 45 citing articles:
CAR-T cell combination therapy: the next revolution in cancer treatment
Maysoon Al‐Haideri, Santalia Banne Tondok, Salar Hozhabri Safa, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 82
Maysoon Al‐Haideri, Santalia Banne Tondok, Salar Hozhabri Safa, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 82
Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy
Simona Ruxandra Volovăț, Dragoş Viorel Scripcariu, Ingrid-Andrada Vasilache, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1180-1180
Open Access | Times Cited: 19
Simona Ruxandra Volovăț, Dragoş Viorel Scripcariu, Ingrid-Andrada Vasilache, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1180-1180
Open Access | Times Cited: 19
Nano based-oncolytic viruses for cancer therapy
Mobarakeh Ajam-Hosseini, Fatemeh Akhoondi, Mohammad Doroudian
Critical Reviews in Oncology/Hematology (2023) Vol. 185, pp. 103980-103980
Closed Access | Times Cited: 25
Mobarakeh Ajam-Hosseini, Fatemeh Akhoondi, Mohammad Doroudian
Critical Reviews in Oncology/Hematology (2023) Vol. 185, pp. 103980-103980
Closed Access | Times Cited: 25
Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?
Christianne Groeneveldt, Jasper van den Ende, Nadine van Montfoort
Cytokine & Growth Factor Reviews (2023) Vol. 70, pp. 1-12
Open Access | Times Cited: 24
Christianne Groeneveldt, Jasper van den Ende, Nadine van Montfoort
Cytokine & Growth Factor Reviews (2023) Vol. 70, pp. 1-12
Open Access | Times Cited: 24
Application of oncolytic virus in tumor therapy
Zhijian Huang, Hongen Guo, Lin Lin, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 23
Zhijian Huang, Hongen Guo, Lin Lin, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 23
Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy
Shashi Gujar, Jonathan Pol, K. Vishnupriyan, et al.
Nature Protocols (2024) Vol. 19, Iss. 9, pp. 2540-2570
Closed Access | Times Cited: 13
Shashi Gujar, Jonathan Pol, K. Vishnupriyan, et al.
Nature Protocols (2024) Vol. 19, Iss. 9, pp. 2540-2570
Closed Access | Times Cited: 13
Unmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma
Narimene Beder, Seyedeh Nasim Mirbahari, Mourad Belkhelfa, et al.
Exploration of Targeted Anti-tumor Therapy (2025)
Open Access
Narimene Beder, Seyedeh Nasim Mirbahari, Mourad Belkhelfa, et al.
Exploration of Targeted Anti-tumor Therapy (2025)
Open Access
Integrating innate and adaptive immunity in oncolytic virus therapy
Kristin DePeaux, Greg M. Delgoffe
Trends in cancer (2023) Vol. 10, Iss. 2, pp. 135-146
Open Access | Times Cited: 13
Kristin DePeaux, Greg M. Delgoffe
Trends in cancer (2023) Vol. 10, Iss. 2, pp. 135-146
Open Access | Times Cited: 13
The role of oncolytic virotherapy and viral oncogenes in the cancer stem cells: a review of virus in cancer stem cells
Amirhosein Faghihkhorasani, Alaleh Dalvand, Ehsan Derafsh, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Amirhosein Faghihkhorasani, Alaleh Dalvand, Ehsan Derafsh, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 13
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa, Peter R. Galle, Yee Chao, et al.
Liver Cancer (2023) Vol. 13, Iss. 3, pp. 256-272
Open Access | Times Cited: 11
Ghassan K. Abou‐Alfa, Peter R. Galle, Yee Chao, et al.
Liver Cancer (2023) Vol. 13, Iss. 3, pp. 256-272
Open Access | Times Cited: 11
Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Hong Zheng, Xiaoqing Yu, Mohammed L. Ibrahim, et al.
Cancer Immunology Research (2023) Vol. 11, Iss. 4, pp. 466-485
Open Access | Times Cited: 8
Hong Zheng, Xiaoqing Yu, Mohammed L. Ibrahim, et al.
Cancer Immunology Research (2023) Vol. 11, Iss. 4, pp. 466-485
Open Access | Times Cited: 8
Zika Virus: A Neurotropic Warrior against High-Grade Gliomas—Unveiling Its Potential for Oncolytic Virotherapy
María-Angélica Calderón-Peláez, Silvia Maradei Anaya, Ingrid Bedoya-Rodríguez, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 561-561
Open Access | Times Cited: 2
María-Angélica Calderón-Peláez, Silvia Maradei Anaya, Ingrid Bedoya-Rodríguez, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 561-561
Open Access | Times Cited: 2
Present and Future of Immunotherapy for Triple-Negative Breast Cancer
Sushmitha Sriramulu, Shivani Thoidingjam, Corey Speers, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3250-3250
Open Access | Times Cited: 2
Sushmitha Sriramulu, Shivani Thoidingjam, Corey Speers, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3250-3250
Open Access | Times Cited: 2
Developing Oncolytic Viruses for the Treatment of Cervical Cancer
Eleni Kalafati, Ekati Drakopoulou, Nicholas P. Anagnou, et al.
Cells (2023) Vol. 12, Iss. 14, pp. 1838-1838
Open Access | Times Cited: 7
Eleni Kalafati, Ekati Drakopoulou, Nicholas P. Anagnou, et al.
Cells (2023) Vol. 12, Iss. 14, pp. 1838-1838
Open Access | Times Cited: 7
Oncolytic virus preclinical toxicology studies
Agnija Rasa, Pēteris Alberts
Journal of Applied Toxicology (2022) Vol. 43, Iss. 5, pp. 620-648
Closed Access | Times Cited: 11
Agnija Rasa, Pēteris Alberts
Journal of Applied Toxicology (2022) Vol. 43, Iss. 5, pp. 620-648
Closed Access | Times Cited: 11
Flaviviruses in AntiTumor Therapy
Alina S. Nazarenko, Mikhail F. Vorovitch, Yulia K. Biryukova, et al.
Viruses (2023) Vol. 15, Iss. 10, pp. 1973-1973
Open Access | Times Cited: 6
Alina S. Nazarenko, Mikhail F. Vorovitch, Yulia K. Biryukova, et al.
Viruses (2023) Vol. 15, Iss. 10, pp. 1973-1973
Open Access | Times Cited: 6
Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
Richard Kolade Omole, Oluwaseyi Oluwatola, Millicent Tambari Akere, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 10
Richard Kolade Omole, Oluwaseyi Oluwatola, Millicent Tambari Akere, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 10
Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
Maryam Sadri, Alireza Najafi, Ali Rahimi, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110470-110470
Closed Access | Times Cited: 5
Maryam Sadri, Alireza Najafi, Ali Rahimi, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110470-110470
Closed Access | Times Cited: 5
Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors
Stavros Sotiriadis, Julia Beil, Susanne Berchtold, et al.
Viruses (2024) Vol. 16, Iss. 5, pp. 775-775
Open Access | Times Cited: 1
Stavros Sotiriadis, Julia Beil, Susanne Berchtold, et al.
Viruses (2024) Vol. 16, Iss. 5, pp. 775-775
Open Access | Times Cited: 1
Present and Future of Immunotherapy for Triple-Negative Breast Cancer
Sushmitha Sriramulu, Shivani Thoidingjam, Corey Speers, et al.
(2024)
Open Access | Times Cited: 1
Sushmitha Sriramulu, Shivani Thoidingjam, Corey Speers, et al.
(2024)
Open Access | Times Cited: 1
Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma
Linus D. Kloker, Branko Calukovic, Katrin Benzler, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Linus D. Kloker, Branko Calukovic, Katrin Benzler, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Intranasal Delivery of Oncolytic Adenovirus XVir-N-31 via Optimized Shuttle Cells Significantly Extends Survival of Glioblastoma-Bearing Mice
Ali El-Ayoubi, Moritz Klawitter, Jakob Rüttinger, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 4912-4912
Open Access | Times Cited: 4
Ali El-Ayoubi, Moritz Klawitter, Jakob Rüttinger, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 4912-4912
Open Access | Times Cited: 4
Oncolytic virotherapy using neural stem cells as a novel treatment option for glioblastoma multiforme
Tanvir Ahmed
MedComm – Oncology (2023) Vol. 2, Iss. 1
Open Access | Times Cited: 3
Tanvir Ahmed
MedComm – Oncology (2023) Vol. 2, Iss. 1
Open Access | Times Cited: 3
Reovirus infection of tumor cells reduces the expression of NKG2D ligands, leading to impaired NK-cell cytotoxicity and functionality
Raghad Khaleafi, Jelena Železnjak, Sapir Cordela, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Raghad Khaleafi, Jelena Železnjak, Sapir Cordela, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies
Christopher J. Fay, Samantha Jakuboski, Beth N. McLellan, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 765-785
Closed Access | Times Cited: 2
Christopher J. Fay, Samantha Jakuboski, Beth N. McLellan, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 765-785
Closed Access | Times Cited: 2
